Applied Therapeutics Inc
NASDAQ:APLT
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.84
10.24
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one APLT stock under the Base Case scenario is 6.71 USD. Compared to the current market price of 9.625 USD, Applied Therapeutics Inc is Overvalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Applied Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for APLT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Applied Therapeutics Inc
Balance Sheet Decomposition
Applied Therapeutics Inc
Current Assets | 104.6m |
Cash & Short-Term Investments | 99.1m |
Receivables | 262k |
Other Current Assets | 5.2m |
Non-Current Assets | 2m |
PP&E | 2m |
Current Liabilities | 99m |
Accounts Payable | 2.8m |
Accrued Liabilities | 13m |
Other Current Liabilities | 83.1m |
Non-Current Liabilities | 1.7m |
Other Non-Current Liabilities | 1.7m |
Earnings Waterfall
Applied Therapeutics Inc
Revenue
|
10.4m
USD
|
Operating Expenses
|
-146.3m
USD
|
Operating Income
|
-135.8m
USD
|
Other Expenses
|
-133.6m
USD
|
Net Income
|
-269.4m
USD
|
Free Cash Flow Analysis
Applied Therapeutics Inc
USD | |
Free Cash Flow | USD |
APLT Profitability Score
Profitability Due Diligence
Applied Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Applied Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
APLT Solvency Score
Solvency Due Diligence
Applied Therapeutics Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Applied Therapeutics Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
APLT Price Targets Summary
Applied Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for APLT is 13.056 USD with a low forecast of 11.11 USD and a high forecast of 14.7 USD.
Dividends
Current shareholder yield for APLT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
APLT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).
Contact
IPO
Employees
Officers
The intrinsic value of one APLT stock under the Base Case scenario is 6.71 USD.
Compared to the current market price of 9.625 USD, Applied Therapeutics Inc is Overvalued by 30%.